Advancing the Discovery & Development of Peptide Drugs with Novel Screening, Chemistry, Formulation & CMC to Improve Permeability, Bioavailability & Efficacy Across All Diseases
Peptide therapies are rapidly becoming a disruptive modality, with Unnatural Products scoring a potential $1.7bn licensing agreement with Novartis for macrocyclic peptide therapeutics and Zonsen PepLib Biotech entering R&D collaboration with Eli Lilly to advance the novel peptide-based drugs in the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
Gathering industry leaders including Unnatural Products, Parabilis Medicines, Circle Pharma, Abbvie, Eli Lilly, Merck, Johnson & Johnson, Chugai Pharmaceuticals, Bayer and many more, this is your premium forum to explore the power of peptide computation, optimizing analytics, improving oral bioavailability and translating the pharmacology with clinical safety.
Join 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.
Attending Companies Include